Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.

ABSTRACT:

Background

The low expectation of clinical benefit from phase 1 cancer therapeutics trials might negatively affect patient and physician participation, study reimbursement, and slow the progress of oncology research. Advances in cancer drug development, meanwhile, might have favourably improved treatment responses; however, little comprehensive data exist describing the response and toxicity associated with phase 1 trials across solid tumours. The aim of the study is to evaluate the trend of toxicity and response in phase 1 trials for solid tumours over time.

Methods

We analysed patient-level data from the Cancer Therapy Evaluation Program of the National Cancer Institute-sponsored investigator-initiated phase 1 trials for solid tumours, from Jan 1, 2000, to May 31, 2019. We

SUBMITTER: Chihara D 

PROVIDER: S-EPMC9477645 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature